Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2017

01-07-2017 | Research Article

Predictive factors for survival in neoadjuvant radiochemotherapy for advanced rectal cancer

Authors: A. Reig Castillejo, I. Membrive, P. Foro, J. Quera, X. Sanz, N. Rodriguez, E. Fernández-Velilla, O. Pera, A. Ortiz, M. Algara

Published in: Clinical and Translational Oncology | Issue 7/2017

Login to get access

Abstract

Introduction

Neoadjuvant radiochemotherapy followed by radical surgery is the standard approach in advanced rectal carcinoma. Tumor response is determined in histological specimen.

Objective

To assess predictive factors for survival in 115 patients.

Patients and Method

115 patients treated with neoadjuvant radiochemotherapy followed by radical surgery with total mesorectal excision, in our hospital from January 2007 to December 2014. All patients received pelvic radiotherapy with concomitant chemotherapy, followed by radical surgery and in some adjuvant chemotherapy.

Results

In univariate analysis, distance to anal verge, radial margin, perineural invasion, and good grade regression are predictive factors for both, specific and disease free survival; and in multivariant, only radial margin and perineural invasion were predictive factors for survival. We found distance to anal verge (<5 cm) as the only clinical factor to predict a positive margin in the histologic specimen.

Conclusions

Perineural invasion and positive radial margin are predictive factors for both specific and disease free survival.
Literature
1.
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fiethav R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed
2.
Jones WE, Thomas CR, Herman JM, Abdel-Wahob M, Azad N, Blackstock W, et al. ACR appropriateness criteria resectable rectal cancer. Radiat Oncol. 2012;7:16135.CrossRef
3.
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henrey-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathological Correl Cancer. 1994;73:2680–6.
4.
Bouzourene H, Bosman FT, Seelentag W, Matter M, Couche P, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002;94:1121–30.CrossRefPubMed
5.
Roh MS, Colangelo LH, O´Conell MJ, Yothers G, Deutsch H, Allegra CJ, et al. Preoperative multimodality therapy improves disease free survival in patients with carcinoma of the rectum. J Clin Oncol. 2009;27:5124–30.CrossRefPubMedPubMedCentral
6.
Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kvo LJ, et al. Long term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMed
7.
Kapiteijn E, Marijnen CA, Nagtegaal, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cáncer. N Engl J Med. 2001;345:638–46.CrossRefPubMed
8.
Habr Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro V, Silva E, Sousa AH, et al. Long term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg. 2005;9:90–9.CrossRefPubMed
9.
Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long term outcomes and prognostic significance of pathologic nodal status. Ann Surg. 2010;252:998–1004.CrossRefPubMed
10.
de Campos-Lobato LF, Stocchi L, da Moreira L, Geister D, Dietz DW, Lavery IC, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011;18:1590–8.CrossRefPubMed
11.
Compton CC, Fielding LP, Burgart LI, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124:979–94.PubMed
12.
Stephen B Edge MC, David R Byrd MD, Carolyn C, Compton MD et al. TMN classification of malignant tumors 7th edition. AJCC. Chicago: Springer; 2010
13.
Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, et al. Nomograms for predicting local recurrence, distant metastases and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J ClinOncol. 2011;29:3163–72.CrossRef
14.
Glimelius B, Tiret E, Cervantes A, Arnold D, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2013;248(suppl6):81–8.
15.
Lim SH, Chua W, Henderson C, Shin J-S, Chantrill L, Asgharics R, Lee, et al. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit Rev Oncol Hematol. 2015;96(1):67–80.CrossRefPubMed
16.
Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMed
17.
Priyanka C, Phuong N, Xueliang P, Robeinson Andrew BA, Walston Steve DO, Christina Wu, et al. Perineural invasion predicts for distant metastases in locally advanced rectal cancer treated with neoadjuvant chemoradiation and surgery. Am J Clin Oncol. 2015;39(12):1635–42.
18.
Liebig C, Ayala G, Wilks J, Berger AH, Albo D, et al. Perineural invasion in cancer: a review of the literature. Cancer. 2009;115:3379–91.CrossRefPubMed
19.
Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol. 2009;27:5131–7.CrossRefPubMedPubMedCentral
20.
Cienfuegos JA, Rotellar F, Baixauli J, Beortegui C, Sola JJ, Arbea L, et al. Impact of perineural and lympho vascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. Ann Surg Oncol. 2014;22:916–23.CrossRefPubMed
21.
Huang CM, Huang CW, Huang MY, Lin CH, Chen CF, Yeh YS, et al. Coexistence of perineural invasion and lymph node metastases is a poor prognostic factor in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by radical resection and adjuvant chemotherapy. Med Princ Pract. 2014;23:465–70.CrossRefPubMed
22.
de Caria K, Rahal R, Niu J, Lockwood G, Bryant H, Math M, et al. Rectal cancer resection and circumferential margin rates in Canada: a population-based study. Curr Oncol. 2015;22(1):60–3.
23.
Dhadda AS, Besell EM, Scholefield J, Dickinson P, Zaitoun AM, et al. Mandardtumour regression grade, perineural invasion, circumferential resection margin and post chemoradiation nodal status strongly predict outcome in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Clin Oncol. 2014;26:197–202.CrossRef
24.
Zhang Z, Wang M, Zhou L, Fenq X, Cheng J, Yu Y, et al. Increased HMGB1 and cleaved caspase3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res. 2015;34:51.CrossRefPubMedPubMedCentral
25.
Wang J, Cui F, Wang X, Xue Y, Chen J, Yu Y, et al. Elevated kinesin family member 26B is a prognostic biomarker and a potential therapeutic target for colorectal cancer. J Exp Clin Cancer Res. 2015;34:13.CrossRefPubMedPubMedCentral
26.
Renehan AJ, Malcomson LBS, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch and wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer: a propensity score matched cohort analysis. Lancet Oncol. 2016;17(2):174–83.CrossRefPubMed
Metadata
Title
Predictive factors for survival in neoadjuvant radiochemotherapy for advanced rectal cancer
Authors
A. Reig Castillejo
I. Membrive
P. Foro
J. Quera
X. Sanz
N. Rodriguez
E. Fernández-Velilla
O. Pera
A. Ortiz
M. Algara
Publication date
01-07-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1612-7

Other articles of this Issue 7/2017

Clinical and Translational Oncology 7/2017 Go to the issue

Brief Research Article

Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy

Research Article

KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

Research Article

Effects of low-dose radiation on adaptive response in colon cancer stem cells

Research Article

Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies

Research Article

Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer

Review Article

Retroperitoneal lymph node dissection: an update in testicular malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits